Clinical Trial Detail

NCT ID NCT02650635
Title TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Mayo Clinic
Indications

renal cell carcinoma

melanoma

lung non-small cell carcinoma

pancreatic adenocarcinoma

colorectal adenocarcinoma

breast cancer

Advanced Solid Tumor

Therapies

Cyclophosphamide + Motolimod + Pegfilgrastim

Age Groups: adult

No variant requirements are available.